AstraZeneca, Eli Lilly begin large trial for Alzheimer's drug

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

After teaming up in September to develop its experimental Alzheimer's drug, AstraZeneca (NYSE:AZN) and partner Eli Lilly (NYSE:LLY) have begun a large trial for the product, known as AZD3293 or LY3314814.

The pivotal Phase II/III clinical trial will involve more than 1,500 patients with early Alzheimer's and is expected to be completed in 2019.

Subscribe for full text news in your inbox